Navigation Links
Head-to-Head Study Demonstrates Focalin(R) XR Offers Faster and Better Symptom Control than Concerta(R)1 in Early Part of ADHD Patients' Day
Date:7/8/2008

or government regulation generally; unexpected clinical trial results, including unexpected new clinical data, and unexpected additional analysis of existing clinical data; the company's ability to obtain or maintain patent or other proprietary intellectual property protection; competition in general; increased government, industry, and general public pricing pressures; and other risks and factors referred to in Novartis AG's current Form 20-F on file with the U.S. Securities and Exchange Commission. Should one or more of these risks or uncertainties materialize, or should underlying assumptions prove incorrect, actual results may vary materially from those anticipated, believed, estimated or expected. Novartis is providing the information in this press release as of this date and does not undertake any obligation to update any forward-looking statements contained in this press release as a result of new information, future events or otherwise.

About Novartis

Novartis Pharmaceuticals Corporation researches, develops, manufactures and markets leading innovative prescription drugs used to treat a number of diseases and conditions, including those in the cardiovascular, metabolic, cancer, organ transplantation, central nervous system, dermatological, GI and respiratory areas. The company's mission is to improve people's lives by pioneering novel healthcare solutions.

Located in East Hanover, New Jersey, Novartis Pharmaceuticals Corporation is an affiliate of Novartis AG (NYSE: NVS), which provides healthcare solutions that address the evolving needs of patients and societies. Focused solely on growth areas in healthcare, Novartis offers a diversified portfolio to best meet these needs: innovative medicines, cost-saving generic p
'/>"/>

SOURCE Novartis Pharmaceuticals Corporation
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related medicine technology :

1. Two-Year Outcomes From Large Head-to-Head Clinical Trial Indicate Similar Safety Profile in Diabetic Patients for Cypher(R) Sirolimus-Eluting Coronary Stent and Taxus Stent
2. Cleveland Clinic to Lead First Head-to-Head Comparison of the Two Most Potent Statins
3. New Data From Head-to-Head Study Confirms Once-Daily Levemir(R) is as Effective as Glargine over a 24-Hour Period in Subjects with Type 2 Diabetes
4. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
5. EDAP Announces Launch of Clinical Study Combining HIFU and Chemotherapy for Localized Aggressive High Risk Prostate Cancer
6. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
7. Allos Therapeutics Initiates Study of PDX in Patients with Cutaneous T-Cell Lymphoma
8. Multiple Myeloma Research Consortium (MMRC) Partners with Novartis to Advance Phase II Study of Deacetylase Inhibitor
9. Potential Safety Issue Identified in Ongoing Phase 2 Clinical Study of HCV-796
10. Study Suggests High-Dose Fish Oil May Significantly Improve Behavior in Children with ADHD
11. MicroDose Announces Positive Results From the QDose Inhaled Insulin Glucose Clamp Study
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/24/2014)... -- Marta Rendon, MD, founder of the Rendon Center for Dermatology ... international key opinion leader in dermatology, was one of only ... to attend the international Aesthetic Experts Summit held ... at this gathering of over 600 physicians from 57 countries, ... experts from Asia and ...
(Date:11/24/2014)...  AiCure, an artificial intelligence company providing advanced ... ingestion, has announced the start of a major ... receiving medication as maintenance therapy for opioid addiction. ... have quadrupled in the last 15 years. Opioids ... cocaine and benzodiazepines combined. Overall, the economic cost ...
(Date:11/24/2014)... 2014  Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL ) ... the board of directors and from his positions as chairman ... recently serving as the company,s president and chief operating officer, ... the board of directors.  Gary Lyons , a member ... Mr. Gower is expected to remain an employee until the ...
Breaking Medicine Technology:Marta Rendon, MD Selected To Attend Prestigious, Global Aesthetic Experts Summit! 2Marta Rendon, MD Selected To Attend Prestigious, Global Aesthetic Experts Summit! 3Can artificial intelligence solve the $55 billion problem of opioid abuse? 2Rigel Announces Executive Management Changes 2Rigel Announces Executive Management Changes 3
... FRIMLEY, England, May 20 , - Tasigna(R) ... to Prior Treatment in the Chronic (Early) Phase ... Nature of Tasigna(R) Tackles the Root Cause of ... - Tasigna Expands CML Portfolio for Novartis, ...
... Similar to, Native Bladder by Six Months; Data Presented at May ... ... Session, ORLANDO, Fla. and EAST NORRITON, Pa., May 19 ... and neo-vessels, presented preclinical efficacy data for its,Tengion Neo-Bladder Replacement(TM) at ...
Cached Medicine Technology:Launch of Highly Targeted Cancer Treatment Tasigna(R) (nilotinib) Offers Potential Lifeline to Ph+ CML Patients Intolerant or Resistant to Existing Therapies, Including Glivec(R) (imatinib) 2Launch of Highly Targeted Cancer Treatment Tasigna(R) (nilotinib) Offers Potential Lifeline to Ph+ CML Patients Intolerant or Resistant to Existing Therapies, Including Glivec(R) (imatinib) 3Launch of Highly Targeted Cancer Treatment Tasigna(R) (nilotinib) Offers Potential Lifeline to Ph+ CML Patients Intolerant or Resistant to Existing Therapies, Including Glivec(R) (imatinib) 4Launch of Highly Targeted Cancer Treatment Tasigna(R) (nilotinib) Offers Potential Lifeline to Ph+ CML Patients Intolerant or Resistant to Existing Therapies, Including Glivec(R) (imatinib) 5Preclinical Data Demonstrate Ability to Regenerate an Entire Bladder With Tengion Neo-Bladder Replacement(TM) 2
(Date:11/26/2014)... Obispo, CA (PRWEB) November 26, 2014 ... is offering lower prices in an early celebration of ... Bunion Booties are being offered at the promotional price ... promotional pricing is in addition to any automatic discounts ... the Bunion Bootie website for complete details. ...
(Date:11/26/2014)... News Facts , Lexmark’s ... RSNA 2014 in Chicago. The company will demonstrate ... images, photos, videos and documents found throughout the ... learn more about these innovative medical content management ... initiatives – that enable more informed clinical decisions, ...
(Date:11/26/2014)... -- Youngsters who enter puberty early are at increased ... puberty was linked with a number of factors associated ... levels, according to the researchers. Early puberty was also ... and peers, and having friends who were prone to ... study found an association between early puberty and these ...
(Date:11/26/2014)... -- The number of emergency department visits in the United ... record 136 million in 2011, according to the U.S. Centers ... that fewer people were going to ERs with non-urgent medical ... care within two hours of arriving at the ER. In ... Sixty percent of patients arrived at the ER after ...
(Date:11/26/2014)... HealthDay Reporter TUESDAY, Nov. 25, ... Nexium may disrupt the makeup of bacteria in the digestive ... a small new study suggests. The research doesn,t ... become ill, and study authors aren,t recommending that anyone stop ... "should be used at the lowest dose that provides adequate ...
Breaking Medicine News(10 mins):Health News:Bunion Bootie Temporarily Lowering Prices for Holiday Shopping, Starting Today! 2Health News:Perceptive Software to Demonstrate New Medical Content Management Features and Capabilities at RSNA 2014 2Health News:Perceptive Software to Demonstrate New Medical Content Management Features and Capabilities at RSNA 2014 3Health News:Early Puberty Linked to Increased Risk of Depression in Teens 2Health News:ER Visits on the Rise, Study Reports 2Health News:Could Popular Heartburn Drugs Upset Your 'Good' Gut Bugs? 2Health News:Could Popular Heartburn Drugs Upset Your 'Good' Gut Bugs? 3
... in the pancreas, but in the brain as well. When ... can be brain cell death and subsequent development of the ... was conducted in rats, and it was identified that insulin ... produced in the nerve cells, neurons in several brain regions. ...
... of the International Association for Dental Research held in ... a study// that says eating sugar-free yogurt is good ... odor or so called bad breath is caused by ... study revealed that volunteers who had sugar-free more and ...
... in the juice of pomegranate may help in reducing ... process of plaques etc forming in the inner lining ... state of atherosclerosis. This causes disturbed blood flow and ... the risk of atherogenesis. ,The new study ...
... has found out that depression has to be blamed for ... to treat the same. The study was conducted on 60,000 ... results showed both the newer and older classes of antidepressants ... first month of being prescribed.The older class of tricyclic antidepressants ...
... Diabetes Care, March 2005, scientists have reported that caffeine may ... the measure for the risk of heart disease. If a ... risk of heart problems. ,Diabetes type 2 happens when ... As this happens the body becomes unable to produce enough ...
... administration of the drug tezosentan did not improve worsening heart ... // despite high hopes. The above fact was found out ... date. The study was conducted to evaluate if something more ... to speed up hospital discharge and prevent them from coming ...
Cached Medicine News:
... Helmer PC1200 Platelet Incubators ... your laboratory counter top. These ... institution to have the security ... environment without taking up a ...
The PC4200i is the largest capacity platelet incubator available. It features a built-in agitator with a capacity of 396 random bags (132 apheresis)....
... Platelet incubators hold rotators and ... temperature can be set at ... 15C to 40C (59F to ... from top to bottom. Recorder ...
An enzyme-linked immuno-sorbent assay for the detection and quantitation of anti-tissue Transglutaminase in serum of patients with Celiac Disease and Dermatitis Herpetiformis....
Medicine Products: